Minimal/measurable Residual Disease in AML: a Consensus Document from the European LeukemiaNet MRD Working Party

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2018 Jan 14

PMID 29330221

Citations 436

Authors

Gerrit J Schuurhuis

Michael Heuser

Sylvie Freeman

Marie-Christine Bene

Francesco Buccisano

Jacqueline Cloos

David Grimwade

Torsten Haferlach

Robert K Hills

Christopher S Hourigan

Jeffrey L Jorgensen

Wolfgang Kern

Francis Lacombe

Luca Maurillo

Claude Preudhomme

Bert A van der Reijden

Christian Thiede

Adriano Venditti

Paresh Vyas

Brent L Wood

Roland B Walter

Konstanze Dohner

Gail J Roboz

Gert J Ossenkoppele

Affiliations

Soon will be listed here.

Abstract

Measurable residual disease (MRD; previously termed minimal residual disease) is an independent, postdiagnosis, prognostic indicator in acute myeloid leukemia (AML) that is important for risk stratification and treatment planning, in conjunction with other well-established clinical, cytogenetic, and molecular data assessed at diagnosis. MRD can be evaluated using a variety of multiparameter flow cytometry and molecular protocols, but, to date, these approaches have not been qualitatively or quantitatively standardized, making their use in clinical practice challenging. The objective of this work was to identify key clinical and scientific issues in the measurement and application of MRD in AML, to achieve consensus on these issues, and to provide guidelines for the current and future use of MRD in clinical practice. The work was accomplished over 2 years, during 4 meetings by a specially designated MRD Working Party of the European LeukemiaNet. The group included 24 faculty with expertise in AML hematopathology, molecular diagnostics, clinical trials, and clinical medicine, from 19 institutions in Europe and the United States.

Citing Articles

Impact of high-sensitivity flow cytometry on peri-transplant minimal residual disease kinetics in acute leukemia.

de Azambuja A, Beltrame M, Malvezzi M, Schluga Y, Justus J, Lima A Sci Rep. 2025; 15(1):6942.

PMID: 40011589 PMC: 11865467. DOI: 10.1038/s41598-025-91936-7.

Cellular automata modelling of leukaemic stem cell dynamics in acute myeloid leukaemia: insights into predictive outcomes and targeted therapies.

Saikawa Y, Komatsuzaki T, Nishiyama N, Hatta T R Soc Open Sci. 2025; 12(1):241202.

PMID: 39816742 PMC: 11734627. DOI: 10.1098/rsos.241202.

Efficacy of geneguided preemptive therapy for prevention of relapse in acute myeloid leukemia after transplantation and its optimal intervention threshold.

Fang P, Gao Y, Xin H, Liu L, Liu Y, Xu Y Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2025; 49(7):1120-1129.

PMID: 39788500 PMC: 11495973. DOI: 10.11817/j.issn.1672-7347.2024.240351.

Breaking the Bone Marrow Barrier: Peripheral Blood as a Gateway to Measurable Residual Disease Detection in Acute Myelogenous Leukemia.

Butler J, Yashar W, Swords R Am J Hematol. 2025; 100(4):638-651.

PMID: 39777414 PMC: 11886496. DOI: 10.1002/ajh.27586.

TIM-3 marks measurable residual leukemic stem cells responsible for relapse after allogeneic stem cell transplantation.

Sakoda T, Kikushige Y, Irifune H, Kawano G, Harada T, Semba Y Cancer Sci. 2024; 116(3):698-709.

PMID: 39726280 PMC: 11875787. DOI: 10.1111/cas.16431.

References

Beillard E, Pallisgaard N, van der Velden V, Bi W, Dee R, van der Schoot E . Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program. Leukemia. 2003; 17(12):2474-86. DOI: 10.1038/sj.leu.2403136. View

Zhou Y, Othus M, Araki D, Wood B, Radich J, Halpern A . Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia. Leukemia. 2016; 30(7):1456-64. PMC: 4935622. DOI: 10.1038/leu.2016.46. View

Buccisano F, Maurillo L, Del Principe M, Del Poeta G, Sconocchia G, Lo-Coco F . Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood. 2011; 119(2):332-41. DOI: 10.1182/blood-2011-08-363291. View

Dohner H, Weisdorf D, Bloomfield C . Acute Myeloid Leukemia. N Engl J Med. 2015; 373(12):1136-52. DOI: 10.1056/NEJMra1406184. View

Terwijn M, Zeijlemaker W, Kelder A, Rutten A, Snel A, Scholten W . Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia. PLoS One. 2014; 9(9):e107587. PMC: 4171508. DOI: 10.1371/journal.pone.0107587. View

Loken M, Chu S, Fritschle W, Kalnoski M, Wells D . Normalization of bone marrow aspirates for hemodilution in flow cytometric analyses. Cytometry B Clin Cytom. 2008; 76(1):27-36. DOI: 10.1002/cyto.b.20429. View

Hiatt J, Pritchard C, Salipante S, ORoak B, Shendure J . Single molecule molecular inversion probes for targeted, high-accuracy detection of low-frequency variation. Genome Res. 2013; 23(5):843-54. PMC: 3638140. DOI: 10.1101/gr.147686.112. View

Chen X, Wood B . Monitoring minimal residual disease in acute leukemia: Technical challenges and interpretive complexities. Blood Rev. 2016; 31(2):63-75. DOI: 10.1016/j.blre.2016.09.006. View

Venditti A, Buccisano F, Del Poeta G, Maurillo L, Tamburini A, Cox C . Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood. 2000; 96(12):3948-52. View

10.

Ho T, LaMere M, Stevens B, Ashton J, Myers J, ODwyer K . Evolution of acute myelogenous leukemia stem cell properties after treatment and progression. Blood. 2016; 128(13):1671-8. PMC: 5043124. DOI: 10.1182/blood-2016-02-695312. View

11.

Ossenkoppele G, Schuurhuis G . MRD in AML: does it already guide therapy decision-making?. Hematology Am Soc Hematol Educ Program. 2016; 2016(1):356-365. PMC: 6142473. DOI: 10.1182/asheducation-2016.1.356. View

12.

Gorczyca W, Sun Z, Cronin W, Li X, Mau S, Tugulea S . Immunophenotypic pattern of myeloid populations by flow cytometry analysis. Methods Cell Biol. 2011; 103:221-66. DOI: 10.1016/B978-0-12-385493-3.00010-3. View

13.

Kern W, Voskova D, Schoch C, Hiddemann W, Schnittger S, Haferlach T . Determination of relapse risk based on assessment of minimal residual disease during complete remission by multiparameter flow cytometry in unselected patients with acute myeloid leukemia. Blood. 2004; 104(10):3078-85. DOI: 10.1182/blood-2004-03-1036. View

14.

Alizadeh M, Bernard M, Danic B, Dauriac C, Birebent B, Lapart C . Quantitative assessment of hematopoietic chimerism after bone marrow transplantation by real-time quantitative polymerase chain reaction. Blood. 2002; 99(12):4618-25. DOI: 10.1182/blood.v99.12.4618. View

15.

Zeijlemaker W, Kelder A, Oussoren-Brockhoff Y, Scholten W, Snel A, Veldhuizen D . Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia. Leukemia. 2015; 30(3):708-15. DOI: 10.1038/leu.2015.255. View

16.

Baer M, Stewart C, Dodge R, Leget G, Sule N, Mrozek K . High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361). Blood. 2001; 97(11):3574-80. DOI: 10.1182/blood.v97.11.3574. View

17.

Rubnitz J, Inaba H, Dahl G, Ribeiro R, Bowman W, Taub J . Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010; 11(6):543-52. PMC: 3171799. DOI: 10.1016/S1470-2045(10)70090-5. View

18.

Genovese G, Kahler A, Handsaker R, Lindberg J, Rose S, Bakhoum S . Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371(26):2477-87. PMC: 4290021. DOI: 10.1056/NEJMoa1409405. View

19.

Steensma D, Bejar R, Jaiswal S, Lindsley R, Sekeres M, Hasserjian R . Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015; 126(1):9-16. PMC: 4624443. DOI: 10.1182/blood-2015-03-631747. View

20.

Johansson U, Bloxham D, Couzens S, Jesson J, Morilla R, Erber W . Guidelines on the use of multicolour flow cytometry in the diagnosis of haematological neoplasms. British Committee for Standards in Haematology. Br J Haematol. 2014; 165(4):455-88. DOI: 10.1111/bjh.12789. View